Pharmaceutical service in a case of fat embolism syndrome following postoperative fracture
- VernacularTitle:1例骨折术后并发脂肪栓塞综合征的药学服务
- Author:
Leijiao ZHANG
1
;
Pingping WANG
1
;
Qinqin YAN
1
;
Haiyu HUANG
1
;
Guoxi HUANG
1
;
Xue WU
1
Author Information
1. Dept. of Pharmacy，No. 924 Hospital of PLA Joint Logistic Support Force，Guangxi Guilin 541002，China
- Publication Type:Journal Article
- Keywords:
fat embolism syndrome;
pharmaceutical service;
postoperative fracture;
glucocorticoids;
renal function
- From:
China Pharmacy
2024;35(22):2822-2827
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the pharmaceutical service process in a fracture patient complicated by fat embolism syndrome （FES） following postoperative fracture， aiming to provide a reference for clinical treatment and pharmaceutical service for similar patients. METHODS Clinical pharmacist participated in the entire treatment process of a patient with FES following postoperative fracture. Based on the patient’s clinical manifestations and test results， literature was reviewed to assist clinical physicians in formulating the therapeutic regimen of glucocorticoids. For the drug-related adverse reactions of renal function impairment and reduced platelet count that occurred during the treatment， suspicious drugs were analyzed and disposed of accordingly. RESULTS The clinical pharmacist recommended Hydrocortisone sodium succinate for injection （100 mg， q8 h， ivgtt， for about one week followed by a gradual dose reduction） for treating FES. The Vancomycin hydrochloride for injection used in this case was assessed as “very probably” associated with the adverse drug reactions of renal function impairment and thrombocytopenia. The clinical physician adopted the pharmacist’s medication recommendations， and the patient’s condition stabilized after treatment， with improvement in adverse reactions， and was discharged from the hospital. CONCLUSIONS The use of glucocorticoids in treating FES has a definite therapeutic efficacy. Clinical pharmacists should individualize the medication plan based on the patient’s pathological state and distinguish it from postoperative sepsis. Meanwhile， drug-induced adverse reactions in the kidney and blood system should be closely monitored.
